1-(4-氯苯基)-1-环戊羰酰氯 | 71501-44-5

• 物质功能分类: 化学试剂 - 有机试剂 - 酰卤
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-氯苯基)-1-环戊羰酰氯
• 中文别名: 1-(4-氯苯基)-1-环戊烷羰基氯
• 英文名称: 1-(4-chlorophenyl)-1-cyclopentanecarbonyl chloride
• 英文别名: 1-(4-chlorophenyl)cyclopentane-1-carboxylic acid chloride；1-(4-chlorophenyl)cyclopentanecarbonyl chloride；1-(4-chlorophenyl)cyclopentane-1-carbonyl chloride
• CAS: 71501-44-5
• 化学式: C₁₂H₁₂Cl₂O
• mdl: MFCD00044899
• 分子量: 243.133
• InChiKey: RZHJJILZUKNEKM-UHFFFAOYSA-N

物化性质

• 沸点：
  346.25°C (rough estimate)
• 密度：
  1.1896 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2916399090
• 储存条件：
  室温且干燥环境下使用。

SDS

Name:	1-(4-Chlorophenyl)-1-cyclopentanecarbonyl chloride 97% Material Safety Data Sheet
Synonym:	None
CAS:	71501-44-5

Section 1 - Chemical Product MSDS Name:1-(4-Chlorophenyl)-1-cyclopentanecarbonyl chloride 97% Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
71501-44-5	1-(4-Chlorophenyl)-1-cyclopentanecarbo	97	275-573-5

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 71501-44-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: clear dark brown
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H12Cl2O
Molecular Weight: 243.13

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 71501-44-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(4-Chlorophenyl)-1-cyclopentanecarbonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 71501-44-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 71501-44-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 71501-44-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(4-氯苯基)-1-环戊羰酰氯 在 甲醇 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 N-(3-chlorophenyl)-2-methoxy-4-(1-(4-chlorophenyl)cyclopentane-1-carboxamido)benzamide
  参考文献：
  名称：

  酰胺化合物及其衍生物，制备方法、药物组合物和应用

  摘要：

  本发明公开了一类酰胺化合物及其衍生物，制备方法、药物组合物和应用。该类酰胺化合物结构如式(I)，该类酰胺化合物衍生物涉及所述酰胺化合物的立体异构体、互变异构体、代谢产物、代谢前体、前药、溶剂化物、溶剂化物的盐、结晶、药学上可接受的盐或它们的混合物。该类酰胺化合物及其衍生物对吲哚胺2,3‑双加氧酶1具有高效的抑制作用，可用于制备治疗吲哚胺2,3‑双加氧酶1介导的免疫抑制相关疾病的药物，所制备药物在分子水平即可发挥药效，应用广泛，并且该类化合物合成方法简便，易操作。

  公开号：

  CN113061098B
• 作为产物：
  描述：

  对氯苯乙腈 在 氯化亚砜 、 potassium hydroxide 、 sodium hydroxide 作用下， 以 乙二醇 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 19.5h， 生成 1-(4-氯苯基)-1-环戊羰酰氯
  参考文献：
  名称：

  Synthesis and Biological Activity of Arylcyclopentane-1-carboxylic Acids Aminoesters

  摘要：

  1-Arylcyclopentane-1-carboxylic acids were synthesized by alkaline hydrolysis of the corresponding nitriles. Reactions of the acid chlorides with N,N-dialkylaminoalkyl-and hetarylalkylalkanols provided new aminoester derivatives of 1-arylcyclopentane-1-carboxylic acids. Sympatholytic and adrenolytic activity of the obtained amino esters hydrochlorides was studied.

  DOI：

  10.1134/s107036321905027x

文献信息

• Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation
  作者：Jiahui Tng、Junxian Lim、Kai-Chen Wu、Andrew J. Lucke、Weijun Xu、Robert C. Reid、David P. Fairlie

  DOI：10.1021/acs.jmedchem.0c00230

  日期：2020.6.11

  active inhibitor of histone deacetylases (HDACs) in clinical trials for multiple myeloma, leukemia, and lymphoma. It has few hydrogen bond donors and acceptors but is a chiral 2-arylbutyrate and potentially prone to racemization. We report achiral AR-42 analogues incorporating a cycloalkyl group linked via a quaternary carbon atom, with up to 40-fold increased potency against human class I HDACs (e

  在多发性骨髓瘤，白血病和淋巴瘤的临床试验中，AR-42是组蛋白脱乙酰基酶（HDAC）的口服活性抑制剂。它几乎没有氢键供体和受体，但是是手性的2-芳基丁酸酯，可能易于消旋。我们报道了非手性AR-42类似物，其包含通过季碳原子连接的环烷基，对人类I类HDAC的效力提高了40倍（例如，JT86，IC 500.7 nM，HDAC1），对五种人类癌细胞系的细胞毒性增加了25倍，而对正常人类细胞的毒性降低了多达70倍。JT86在促进MM96L黑色素瘤细胞中乙酰化组蛋白H4积累方面比racAR-42强9倍。分子模型和结构-活性之间的关系支持四氢吡喃与HDAC1的结合，而四氢吡喃则是对酶表面水的疏水屏蔽。这种有效的I类HDAC抑制剂可在AR-42活跃的疾病（癌症，寄生虫感染，炎性疾病）中显示出益处。
• Rapid Asymmetric Synthesis of Disubstituted Allenes by Coupling of Flow-Generated Diazo Compounds and Propargylated Amines
  作者：Jian-Siang Poh、Szabolcs Makai、Timo von Keutz、Duc N. Tran、Claudio Battilocchio、Patrick Pasau、Steven V. Ley

  DOI：10.1002/anie.201611067

  日期：2017.2.6

  We report herein the asymmetric coupling of flow‐generated unstabilized diazo compounds and propargylated amine derivatives, using a new pyridinebis(imidazoline) ligand, a copper catalyst and base. The reaction proceeds rapidly, generating chiral allenes in 10–20 minutes with high enantioselectivity (89–98 % de/ee), moderate yields and a wide functional group tolerance.

  我们在此报告了使用新的吡啶双（咪唑啉）配体，铜催化剂和碱对流动生成的不稳定重氮化合物和炔丙基化的胺衍生物的不对称偶联。反应迅速进行，在10–20分钟内生成手性烯丙基，具有高对映选择性（89–98％de / ee），中等收率和宽泛的官能团耐受性。
• [EN] 2-AMINOTHIAZOLE COMPOUNDS USEFUL AS ASPARTYL PROTEASE INHIBITORS<br/>[FR] COMPOSES DE 2-AMINOTHIAZOLE UTILES EN TANT QU'INHIBITEURS DE L'ASPARTYLE-PROTEASE
  申请人：MERCK & CO INC

  公开号：WO2005097767A1

  公开（公告）日：2005-10-20

  The present invention is directed to 2-aminothiazole compounds which are aspartyl protease inhibitors, and are inhibitors of both the beta-secretase enzyme and HIV protease, and that are useful in the treatment of diseases in which the beta-secretase enzyme and HIV are involved, such as Alzheimer's disease, HIV Infection and AIDS. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme and HIV protease are involved.

  本发明涉及2-氨基噻唑化合物，它们是天冬氨酸蛋白酶抑制剂，同时也是β-分泌酶和HIV蛋白酶的抑制剂，可用于治疗涉及β-分泌酶和HIV的疾病，如阿尔茨海默病、HIV感染和艾滋病。该发明还涉及包含这些化合物的药物组合物，以及在治疗涉及β-分泌酶和HIV蛋白酶的疾病中使用这些化合物和组合物。
• [EN] TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDINE ET LEUR UTILISATION COMME INHIBITEURS DE ASK
  申请人：SERONO LAB

  公开号：WO2009027283A1

  公开（公告）日：2009-03-05

  The present invention relates to triazolopyridine compounds according to Formula (I), their use as medicament, for treating autoimmune disorders, inflammatorydiseases, cardiovascular disceases and/or neurodegenerative diseases and a process for their preparation.

  本发明涉及三唑吡啶化合物，其化学式为（I），其用作药物，用于治疗自身免疫性疾病、炎症性疾病、心血管疾病和/或神经退行性疾病，以及其制备方法。
• Synthesis of 4<i>H</i>-1,3-Benzoxazines via Metal- and Oxidizing Reagent-Free Aromatic C–H Oxygenation
  作者：Fan Xu、Xiang-Yang Qian、Yan-Jie Li、Hai-Chao Xu

  DOI：10.1021/acs.orglett.7b03152

  日期：2017.12.1

  An unprecedented electrochemical aromatic C–H oxygenation reaction for the synthesis of 4H-1,3-benzoxazines from easily available N-benzylamides is reported. These oxidative cyclization reactions proceed in a transition metal- and oxidizing reagent-free fashion and produce H2 as only theoretical byproduct. Adapting the C–H oxygenation reaction in an electrochemical microreactor has been demonstrated

  据报道，从容易获得的N-苄基酰胺类化合物合成4 H -1,3-苯并恶嗪史无前例的电化学芳族CH氧化反应。这些氧化环化反应以无过渡金属和无氧化剂的方式进行，并仅作为理论副产物产生H 2。已经证明了在电化学微反应器中适应CH氧化反应。